Kala Pharmaceuticals Inc expected to post a loss of 36  cents a share - Earnings Preview

KALA BIO

13/05/2022 17:05

* Kala Pharmaceuticals Inc  KALA.OQ   KALA.O  is expected
to show
a fall in quarterly revenue when it reports  results on May 16. 
    * The Arlington Massachusetts-based  company is expected to
report
 a 6.1% decrease in revenue to $3.067 million from $3.27 million
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Kala
Pharmaceuticals Inc
is for a loss of 36 cents per share. For the same quarter last
year, the company reported a loss of 49 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kala
Pharmaceuticals Inc is $5​, above​ its last closing price
of $0.62. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.44       -0.41      -0.68     Missed  -67.2
 Sep. 30 2021  -0.43       -0.43      -0.43     Met     0
 Jun. 30 2021  -0.45       -0.44      -0.57     Missed  -29.5​
 Mar. 31 2021  -0.47       -0.68      -0.49     Beat    28.4
 ​​Dec.        -0.48       -0.46      -0.55     Missed  -20
 31 2020                                                
 Sep. 30 2020  -0.43       -0.44      -0.50     Missed  -12.8​
 Jun. 30 2020  -0.42       -0.41      -0.42     Missed  -1.7
 Mar. 31 2020  -0.42       -0.51      -0.54     Missed  -5.5
 This summary was machine generated May 13 at 16:05 GMT.  All
figures in US dollars  unless otherwise stated